Effect of Drug Targeting Nebulization on Lung Deposition: A Randomized Crossover Scintigraphic Comparison Between Central and Peripheral Delivery

References

1. 1.↵
   1. Laube BL

   . The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005;50(9):1161–1176.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Döring G,
   2. Hoiby N

   . Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004;3(2):67–91.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Ramsey BW,
   2. Dorkin HL,
   3. Eisenberg JD,
   4. Gibson RL,
   5. Harwood IR,
   6. Kravitz RM,
   7. et al

   . Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328(24):1740–1746.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Chuchalin A,
   2. Csiszér E,
   3. Gyurkovics K,
   4. Bartnicka MT,
   5. Sands D,
   6. Kapranov N,
   7. et al

   . A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Paediatr Drugs 2007;9(Suppl 1):21–31.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Berlana D,
   2. Llop JM,
   3. Manresa F,
   4. Jódar R

   . Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis. Pharmacotherapy 2011;31(2):146–157.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Clark AR

   . Understanding penetration index measurements and regional lung targeting. J Aerosol Med Pulm Drug Deliv 2012;25(4):179–187.

   OpenUrlPubMed
7. 7.↵
   1. Heijerman H,
   2. Westerman E,
   3. Conway S,
   4. Touw D,
   5. Döring G

   . Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009;8(5):295–315.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Byrne NM,
   2. Keavey PM,
   3. Perry JD,
   4. Gould FK,
   5. Spencer DA

   . Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis. Arch Dis Child 2003;88(8):715–718.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Hardy JG,
   2. Newman SP,
   3. Knoch M

   . Lung deposition from four nebulizers. Respir Med 1993;87(6):461–465.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Mukhopadhyay S,
    2. Staddon GE,
    3. Eastman C,
    4. Palmer M,
    5. Davies ER,
    6. Carswell F

    . The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med 1994;88(3):203–211.

    OpenUrlPubMedWeb of Science
11. 11.↵
    1. Coates AL,
    2. Green M,
    3. Leung K,
    4. Chan J,
    5. Ribeiro N,
    6. Louca E,
    7. et al

    . Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project. Pediatr Pulmonol 2008;43(8):753–759.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Ilowite JS,
    2. Gorvoy JD,
    3. Smaldone GC

    . Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 1987;136(6):1445–1449.

    OpenUrlPubMedWeb of Science
13. 13.↵
    1. Bauer A,
    2. McGlynn P,
    3. Bovet LL,
    4. Mims PL,
    5. Curry LA,
    6. Hanrahan JP

    . The influence of breathing pattern during nebulization on the delivery of arformoterol using a breath simulator. Respir Care 2009;54(11):1488–1492.

    OpenUrlAbstract/FREE Full Text
14. 14.
    1. Coates AL,
    2. Allen PD,
    3. MacNeish CF,
    4. Ho SL,
    5. Lands LC

    . Effect of size and disease on estimated deposition of drugs administered using jet nebulization in children with cystic fibrosis. Chest 2001;119(4):1123–1130.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Häkkinen AM,
    2. Uusi-Heikkilä H,
    3. Järvinen M,
    4. Saali K,
    5. Karhumäki L

    . The effect of breathing frequency on deposition of drug aerosol using an inhalation-synchronized dosimeter in healthy adults. Clin Physiol 1999;19(3):269–274.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Newman SP,
    2. Woodman G,
    3. Clarke SW

    . Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern. Thorax 1988;43(4):318–322.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Diot P,
    2. Dequin PF,
    3. Rivoire B,
    4. Gagnadoux F,
    5. Faurisson F,
    6. Diot E,
    7. et al

    . Aerosols and anti-infectious agents. J Aerosol Med 2001;14(1):55–64.

    OpenUrlPubMed
18. 18.↵
    1. Dessanges JF

    . A history of nebulization. J Aerosol Med 2001;14(1):65–71.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Geller DE,
    2. Kesser KC

    . The I-neb Adaptive Aerosol Delivery System enhances delivery of α1-antitrypsin with controlled inhalation. J Aerosol Med Pulm Drug Deliv 2010;23(Suppl 1):S55–S59.

    OpenUrlPubMed
20. 20.↵
    1. Brand P,
    2. Friemel I,
    3. Meyer T,
    4. Schulz H,
    5. Heyder J,
    6. Häubetainger K

    . Total deposition of therapeutic particles during spontaneous and controlled inhalations. J Pharm Sci 2000;89(6):724–731.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Brand P,
    2. Meyer T,
    3. Häussermann S,
    4. Schulte M,
    5. Scheuch G,
    6. Bernhard T,
    7. et al

    . Optimum peripheral drug deposition in patients with cystic fibrosis. J Aerosol Med 2005;18(1):45–54.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Coates AL,
    2. Dinh L,
    3. MacNeish CF,
    4. Rollin T,
    5. Gagnon S,
    6. Ho SL,
    7. Lands LC

    . Accounting for radioactivity before and after nebulization of tobramycin to insure accuracy of quantification of lung deposition. J Aerosol Med 2000;13(3):169–178.

    OpenUrlPubMedWeb of Science
23. 23.↵
    1. Miller MR,
    2. Hankinson J,
    3. Brusasco V,
    4. Burgos F,
    5. Casaburi R,
    6. Coates A,
    7. et al

    . Standardisation of spirometry. Eur Respir J 2005;26(2):319–338.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Newman S,
    2. Bennett WD,
    3. Biddiscombe M,
    4. Devadason SG,
    5. Dolovich MB,
    6. Fleming J,
    7. et al

    . Standardization of techniques for using planar (2D) imaging for aerosol deposition assessment of orally inhaled products. J Aerosol Med Pulm Drug Deliv 2012;25(Suppl 1):S10–S28.

    OpenUrlPubMed
25. 25.↵
    1. Köhler E,
    2. Sollich V,
    3. Schuster-Wonka R,
    4. Jorch G

    . Lung deposition after electronically breath-controlled inhalation and manually triggered conventional inhalation in cystic fibrosis patients. J Aerosol Med 2005;18(4):386–395.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Lenney W,
    2. Edenborough F,
    3. Kho P,
    4. Kovarik JM

    . Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. J Cyst Fibros 2011;10(1):9–14.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Brand P,
    2. Beckmann H,
    3. Maas Enriquez M,
    4. Meyer T,
    5. Müllinger B,
    6. Sommerer K,
    7. et al

    . Peripheral deposition of α1-protease inhibitor using commercial inhalation devices. Eur Respir J 2003;22(2):263–267.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. Brand P,
    2. Schulte M,
    3. Wencker M,
    4. Herpich CH,
    5. Klein G,
    6. Hanna K,
    7. Meyer T

    . Lung deposition of inhaled α1-proteinase inhibitor in cystic fibrosis and α1-antitrypsin deficiency. Eur Respir J 2009;34(2):354–360.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. Bakker EM,
    2. Volpi S,
    3. Salonini E,
    4. van der Wiel-Kooij EC,
    5. Sintnicolaas CJ,
    6. Hop WC,
    7. et al

    . Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation. Eur Respir J 2011;38(6):1328–1335.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    1. Nikander K,
    2. Prince I,
    3. Coughlin S,
    4. Warren S,
    5. Taylor G

    . Mode of breathing–tidal or slow and deep–through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of ^99mTc-DTPA. J Aerosol Med Pulm Drug Deliv 2010;23(Suppl 1):S37–S43.

    OpenUrlPubMed
31. 31.↵
    1. Darquenne C

    . Aerosol deposition in health and disease. J Aerosol Med Pulm Drug Deliv 2012;25(3):140–147.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Biddiscombe MF,
    2. Meah SN,
    3. Underwood SR,
    4. Usmani OS

    . Comparing lung regions of interest in gamma scintigraphy for assessing inhaled therapeutic aerosol deposition. J Aerosol Med Pulm Drug Deliv 2011;24(3):165–173.

    OpenUrlPubMed
33. 33.↵
    1. Bennett WD,
    2. Smaldone GC

    . Human variation in the peripheral air-space deposition of inhaled particles. J Appl Physiol 1987;62(4):1603–1610.

    OpenUrlAbstract/FREE Full Text
34. 34.↵
    1. Kendrick AH,
    2. Smith EC,
    3. Wilson RS

    . Selecting and using nebuliser equipment. Thorax 1997;52(Suppl 2):S92–S101.

    OpenUrlPubMedWeb of Science
35. 35.↵
    1. Pitance L,
    2. Vecellio L,
    3. Leal T,
    4. Reychler G,
    5. Reychler H,
    6. Liistro G

    . Delivery efficacy of a vibrating mesh nebulizer and a jet nebulizer under different configurations. J Aerosol Med Pulm Drug Deliv 2010;23(6):389–396.

    OpenUrlPubMed
36. 36.↵
    1. Reychler G,
    2. Keyeux A,
    3. Cremers C,
    4. Veriter C,
    5. Rodenstein DO,
    6. Liistro G

    . Comparison of lung deposition in two types of nebulization: intrapulmonary percussive ventilation vs jet nebulization. Chest 2004;125(2):502–508.

    OpenUrlCrossRefPubMed
37. 37.↵
    1. Bennett WD,
    2. Zeman KL,
    3. Kim C

    . Variability of fine particle deposition in healthy adults: effect of age and gender. Am J Respir Crit Care Med 1996;153(5):1641–1647.

    OpenUrlCrossRefPubMedWeb of Science
38. 38.↵
    1. Kim CS,
    2. Hu SC

    . Total respiratory tract deposition of fine micrometer-sized particles in healthy adults: empirical equations for sex and breathing pattern. J Appl Physiol 2006;101(2):401–412.

    OpenUrlAbstract/FREE Full Text
39. 39.↵
    1. Jaques PA,
    2. Kim CS

    . Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women. Inhal Toxicol 2000;12(8):715–731.

    OpenUrlCrossRefPubMedWeb of Science
40. 40.↵
    1. Kim CS,
    2. Hu SC

    . Regional deposition of inhaled particles in human lungs: comparison between men and women. J Appl Physiol 1998;84(6):1834–1844.

    OpenUrlAbstract/FREE Full Text